ZyVersa gains FDA approval for emergency use of VAR 200 in a rare kidney disease case; stock jumps on high trading volume and ...

Focal Segmental Glomerulosclerosis Market Outlook. Focal Segmental Glomerulosclerosis (FSGS), encompassing diverse conditions like CAD, PAD, and cerebrovascular disease, all rooted in atherosclerosis.

Rheault MN, Alpers CE, Barratt J, et al. Sparsentan versus irbesartan in focal segmental glomerulosclerosis. The New England Journal of Medicine. Published online November 3, 2023. doi:10.1056 ...

Focal segmental glomerulosclerosis (FSGS) still lacks an FDA-approved therapy, but late-breaking post hoc results from the phase III DUPLEX trial -- presented at the National Kidney Foundation ...

Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.

Background. Focal and segmental glomerulosclerosis (FSGS) is the most common histologic pattern of renal injury seen in adults with idiopathic proteinuria. Homozygous or compound heterozygous ...

The two women are scheduled to have the kidney transplant procedure done on Thursday at Tampa General Hospital. TGH says it ...

Chronic kidney disease (CKD) is typically associated with severe fibrosis, the exact pathogenesis of which remains unclear.

A 51-year-old man with a history of non–ST-segment elevation myocardial infarction, hypertension, and focal segmental glomerulosclerosis (FSGS) was admitted to a hospital due to worsening renal ...

Focal segmental glomerulosclerosis (FSGS) is a kidney disease that leads to renal failure, and it affects individuals from different ancestries, the highest prevalence being among African and African ...

Armistice Capital holds 8.9M shares in Travere Therapeutics as rare kidney disease stock climbs 110% following FILSPARI's ...

Diagnosed with focal segmental glomerulosclerosis (FSGS), a rare disease that damages kidney filters, Andrews faced the end of his football dreams and the start of a daunting medical journey.